Profile data is unavailable for this security.
About the company
Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.
- Revenue in USD (TTM)4.83bn
- Net income in USD421.00m
- LocationCatalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
- Phone+1 (732) 537-6200
- Fax+1 (732) 537-6480
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|CTLT:NYQ since |
|Metrics Contract Services||Deal completed||09 Aug 2022||09 Aug 2022Deal completed||-51.34%||475.00m|
|Erytech Pharma SA-Cell Therapy Manufacturing Facility,Princeton,NJ||Deal completed||25 Apr 2022||25 Apr 2022Deal completed||-40.94%||44.50m|
|The Vaccine Manufacturing & Innovation Centre||Deal completed||18 Feb 2022||18 Feb 2022Deal completed||-45.34%||--|